Combination immunotherapy with anti-PD-1/PD-L1 and concomitant targeting of MDSCs such as p38 mitogen-activated protein kinase inhibitors may enhance the efficacy of eradicating tumorigenicity and may prolong survival in the fibrotic HCC mouse model [91]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.